Clinical trials: Hepatitis C Virus (HCV)
Hepatitis C
An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants
The purpose of this study is to investigate the effectiveness and safety of TMC435 compared with placebo in participants who are infected with genotype 1 hepatitis C virus who have never received treatment before.
- Trial name
- QUEST-2 (NCT01290679)
- Testing
- TMC435, Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b), Ribavirin (RBV)
- Where
- 60 sites in United States, Argentina and 13 more
- Volunteers
- 393 people
- Sponsor
- Janssen R&D Ireland
Liver Cancer
The Role of the Vitamin D Receptor Gene Polymorphisms in Hepatocarcinogenesis
Previous data have suggested that vitamin D levels may influence cancer development. In particular, several single nucleotide polymorphisms have been described in the Vitamin D receptor( VDR gene), and some polymorphisms are…
- Trial name
- NCT02461979
- Testing
- The VDR genotype
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sherief Abd-Elsalam
Cirrhosis, Liver
Using Data-Driven Implementation Strategies to Improve the Quality of Cirrhosis Care
This Veteran Affairs (VA) Quality Improvement project aims to understand which data-driven implementation strategies promote evidence based practices that improve high-quality care for Veterans with cirrhosis.
- Trial name
- NCT04178096
- Testing
- Quality Improvement Intervention
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- VA Office of Research and Development
Hepatitis C, Drug Abuse, Intravenous
The TAP Study: Treating People Who Inject Drugs in Community-Based Settings Using a Social Network Approach
This study will investigate the feasibility of treating people who inject drugs (PWID) with hepatitis C virus (HCV) in community-based settings with a 12-week course of oral therapy combination of sofosbuvir plus ledipasvir.
- Trial name
- TAP (NCT02363517)
- Testing
- Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP)
- Where
- Australia
- Volunteers
- 420 people
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Hepatitis C
Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults
This early post-marketing study is an observational, prospective and descriptive study of patients receiving daclatasvir for the treatment of Chronic Hepatitis C at participating sentinel sites for the CNFV in Mexico.
- Trial name
- NCT03181074
- Testing
- Non-Interventional
- Where
- 2 sites in Mexico
- Volunteers
- 10 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C Virus
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection
This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir fixed dose combination (FDC) with or without ribavirin (RBV) administered for 12 or 24 weeks in treatment-experienced subjects…
- Trial name
- ION-2 (NCT01768286)
- Testing
- LDV/SOF, RBV
- Where
- 53 sites in United States
- Volunteers
- 441 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)
This is a non-interventional study designed to evaluate the efficacy and safety of combination study drugs in the treatment of participants diagnosed with Chronic Hepatitis C (CHC).
- Trial name
- NCT01340573
- Testing
- PegIntron Pen, Ribavirin
- Volunteers
- 3 people
- Sponsor
- Merck Sharp & Dohme LLC
HCV Infection ( Genotype 4)
Impact of IL-28B rs12979860 and rs4803217 Gene Polymorphisms Associated With miRNAs Deregulation on HCV-related Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide as well as in Egypt. Despite improvements in HCC therapy, the prognosis for HCC patients remains poor.
- Trial name
- NCT02507882
- Testing
- IL28B Polymorphism, miRNA quantification
- Where
- Egypt
- Volunteers
- 405 people
- Sponsor
- Dr.Waleed Samir
Chronic Hepatitis C
Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir
The purpose of the study is to 1- detect and quantify HCV-PI resistant mutants with ultra-deep pyrosequencing (UDPS) technology, 2 - detect SNPs in P-glyocoprotein and CYP3A genes, in HCV mono-infected patients under/after…
- Trial name
- GENUPI (NCT01577069)
- Where
- France
- Volunteers
- 73 people
- Sponsor
- Association HGE CHU Bordeaux Sud
HIV Infections, Hepatitis C
Treatment of Hepatitis C in Hemophilic Patients With HIV
Pegylated interferon (PEG-interferon) and ribavirin are accepted treatments for hepatitis C virus (HCV) infection. However, HCV infection progresses differently in patients who are coinfected with HIV and in hemophiliacs.
- Conditions
- HIV Infections, Hepatitis C, Hemophilia
- Trial name
- NCT00055341
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Chronic, Cirrhosis, Decompensated
Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection
There are now several licensed drug treatments for patients with HCV infection. These medications have been shown to be very effective in getting rid of the virus in patients with HCV infection including those with early stages…
- Trial name
- NCT02597166
- Testing
- Ledipasvir/Sofosbuvir
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- University Health Network, Toronto
Hepatitis C Infection, Viruses
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
The purpose of this study is to test the safety and efficacy of Civacir® to prevent the recurrence of Hepatitis C Virus (HCV) after liver transplant.
- Conditions
- Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human
- Trial name
- NCT01804829
- Testing
- Civacir® 10%
- Where
- 23 sites in United States
- Volunteers
- 80 people
- Sponsor
- Biotest Pharmaceuticals Corporation
Hepatitis C
Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C)
The purpose of this study is to monitor the cardiovascular and renal health of patients who previously took BMS-986094 (an investigational medication for hepatitis C) in comparison to hepatitis C infected patients who have never…
- Trial name
- CARE-Hep C (NCT01846494)
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 113 people
- Sponsor
- Duke University
Healthy Participants
A Study to Investigate the Potential Pharmacokinetic Interactions Between Phenytoin or Carbamazepine and Telaprevir
The purpose of this study is to investigate the potential pharmacokinetic (what the body does to the drug) interactions between multiple doses of phenytoin 200 mg every 12 hours or carbamazepine 200 mg every 12 hours and…
- Trial name
- NCT01635829
- Testing
- Telaprevir, Phenytoin, Carbamazepine
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Infectious Diseases BVBA
Liver Fibroses, HepatoCellular Carcinoma
Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment
Primary Objective: To evaluate the long-term outcomes including liver related morbidity, mortality and hepatocellular carcinoma (HCC) development as compared to those of historical control with interferon(IFN)-based treatment.
- Conditions
- Liver Fibroses, HepatoCellular Carcinoma, Cryoglobulinemia, Metabolic Disease
- Trial name
- LONGHEAD (NCT03042520)
- Testing
- Observation only
- Where
- 26 sites in South Korea, Taiwan
- Volunteers
- 200 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatitis C
Hepatitis C Virus Self-testing (HCVST) in Sexual and Gender Minorities in Rio de Janeiro
Sexual and gender minorities (SGM), such as gay, bisexual and other men who have sex with men (MSM) and transgender women (TGW), are at high risk of HCV infection.
- Trial name
- NCT06203925
- Testing
- Hepatitis C virus self-test (oral fluid HCVST), Hepatitis C virus self-test (blood-based HCVST)
- Where
- Brazil
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Oswaldo Cruz Foundation
Hepatitis C
Hepatitis C: Community Testing and Treatment (CT2 Study Myanmar)
Implementation-effectiveness hybrid trial assessing acceptability, feasibility and cost-effectiveness of community-based point-of-care testing and treatment for hepatitis C.
- Trial name
- CT2 (NCT03939013)
- Testing
- Xpert HCV VL
- Where
- 2 sites in Burma
- Volunteers
- 634 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Hepatitis C
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and RBV in patients with (Genotype 1) hepatitis C, who did not respond to previous treatment.
- Trial name
- NCT00781274
- Testing
- MP-424, Ribavirin, Peginterferon Alfa-2b
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Tanabe Pharma Corporation
Hepatitis C, Substance Dependence
Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices
The rapid scale up of opioid substitution treatment (OST) for drug users mainly achieved through the possibility of prescribing buprenorphine in primary care has been successful in reducing HIV prevalence among drug users but…
- Conditions
- Hepatitis C, Substance Dependence, Methadone
- Trial name
- Methaville (NCT00657397)
- Testing
- Methadone
- Where
- France
- Volunteers
- 197 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Hepatitis C
T Regulatory Cells in Hepatitis c Infected Patients
Chronic hepatitis C infection is a global worldwide health problem with an increasing burden year-by-year, particularly in areas with a high endemicity like Egypt .
- Trial name
- NCT03186235
- Testing
- Flow cytometry
- Where
- Egypt
- Volunteers
- 88 people
- Sponsor
- Assiut University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.